Search for: "In re Clovis Oncology, Inc. Derivative Litigation" Results 1 - 14 of 14
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Oct 2019, 5:47 am
On October 1, the Delaware Court of Chancery denied a motion to dismiss a Caremark claim in In re Clovis Oncology, Inc. [read post]
7 Oct 2019, 10:59 am by John Jascob
In the latest example, the court held that, for purposes of a motion to dismiss, a shareholder derivative complaint sufficiently pleaded that Clovis Oncology, Inc. [read post]
15 Feb 2023, 9:05 pm by renholding
Barnhill, 212 A.3d 822 (2018). [2] See PWC 2021 Annual Corporate Directors Survey, The Director’s New Playbook: Taking on Change, at 6. [3] See In re Caremark Inc Derivative Litigation, 698 A.2d 959, 970 (Del. [read post]
16 Mar 2020, 1:54 pm by Kevin LaCroix
An early example of Lorenzo having an impact (albeit short-lived) in private litigation is In re Longfin Corp Sec. [read post]
23 Mar 2020, 1:48 pm by Kevin LaCroix
D&O underwriters cannot – and do not – expect that the public company risks they underwrite will never experience a D&O claim, and especially a shareholder class action or derivative claim. [read post]
4 Jan 2021, 1:26 pm by Kevin LaCroix
If the merger objection lawsuits are disregarded, the litigation rate translates to about 4.7%, which although below the record-level litigation rates during the period 2017 -2019 is still well above the 1996-2018 annual litigation rate of 3.0%. [read post]